Immunotherapy resistance: the answers lie ahead – not in front – of us

por Andrews, Miles C., Wargo, Jennifer A.
Publicado 2017

Hallmarks of response to immune checkpoint blockade

por Cogdill, Alexandria P, Andrews, Miles C, Wargo, Jennifer A
Publicado 2017

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy

por Andrews, Miles C., Reuben, Alexandre, Gopalakrishnan, Vancheswaran, Wargo, Jennifer A.
Publicado 2018

Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells

por Woods, Katherine, Pasam, Anupama, Jayachandran, Aparna, Andrews, Miles C., Cebon, Jonathan
Publicado 2014

Systems analysis identifies miR-29b regulation of invasiveness in melanoma

por Andrews, Miles C., Cursons, Joseph, Hurley, Daniel G., Anaka, Matthew, Cebon, Jonathan S., Behren, Andreas, Crampin, Edmund J.
Publicado 2016

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

por Tutuka, Candani S. A., Andrews, Miles C., Mariadason, John M., Ioannidis, Paul, Hudson, Christopher, Cebon, Jonathan, Behren, Andreas
Publicado 2017

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy

por Prithviraj, Prashanth, McArthur, Grant, Atkinson, Victoria, Parente, Phillip, Andrews, Miles, Parakh, Sagun, Millward, Michael, Cebon, Jonathan, Klein, Oliver
Publicado 2015

MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells

por Vella, Laura J, Pasam, Anupama, Dimopoulos, Nektaria, Andrews, Miles, Puaux, Anne-Laure, Louahed, Jamila, Knights, Ashley, Chan, Weisan, Woods, Katherine, Cebon, Jonathan
Publicado 2013

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastat...

por Da Gama Duarte, Jessica, Parakh, Sagun, Andrews, Miles C., Woods, Katherine, Pasam, Anupama, Tutuka, Candani, Ostrouska, Simone, Blackburn, Jonathan M., Behren, Andreas, Cebon, Jonathan
Publicado 2018

Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study

por Wang, Charlie, Zoungas, Sophia, Yan, Mabel, Wolfe, Rory, Haydon, Andrew, Shackleton, Mark, Voskoboynik, Mark, Moore, Maggie, Andrews, Miles C., Nicholls, Stephen J., Mar, Victoria
Publicado 2022

Design, optimisation and standardisation of a high‐dimensional spectral flow cytometry workflow assessing T‐cell immunophenotype in patients with melanoma

por Edwards, Jack M, Andrews, Miles C, Burridge, Hayley, Smith, Robin, Owens, Carole, Edinger, Mark, Pilkington, Katherine, Desfrancois, Juliette, Shackleton, Mark, Senthi, Sashendra, van Zelm, Menno C
Publicado 2023

Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities

por Lee, Belinda, Gately, Lucy, Lok, Sheau Wen, Tran, Ben, Lee, Margaret, Wong, Rachel, Markman, Ben, Dunn, Kate, Wong, Vanessa, Loft, Matthew, Jalili, Azim, Anton, Angelyn, To, Richard, Andrews, Miles, Gibbs, Peter
Publicado 2022

Human perforin mutations and susceptibility to multiple primary cancers

por Trapani, Joseph A., Thia, Kevin Y.T., Andrews, Miles, Davis, Ian D., Gedye, Craig, Parente, Philip, Svobodova, Suzanne, Chia, Jenny, Browne, Kylie, Campbell, Ian G., Phillips, Wayne A., Voskoboinik, Ilia, Cebon, Jonathan S.
Publicado 2013

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

por Wei, Spencer C., Anang, Nana-Ama A. S., Sharma, Roshan, Andrews, Miles C., Reuben, Alexandre, Levine, Jacob H., Cogdill, Alexandria P., Mancuso, James J., Wargo, Jennifer A., Pe’er, Dana, Allison, James P.
Publicado 2019

UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma

por Kuser-Abali, Gamze, Zhang, Youfang, Szeto, Pacman, Zhao, Peinan, Masoumi-Moghaddam, Samar, Fedele, Clare G., Leece, Isobel, Huang, Cheng, Cheung, Jen G., Ameratunga, Malaka, Noguchi, Fumihito, Andrews, Miles C., Wong, Nicholas C., Schittenhelm, Ralf B., Shackleton, Mark
Publicado 2023

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation

por Wang, Minyu, Zadeh, Soroor, Pizzolla, Angela, Thia, Kevin, Gyorki, David E, McArthur, Grant A, Scolyer, Richard A, Long, Georgina, Wilmott, James S, Andrews, Miles C, Au-Yeung, George, Weppler, Ali, Sandhu, Shahneen, Trapani, Joseph A, Davis, Melissa J, Neeson, Paul Joseph
Publicado 2022

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

por Bowyer, Samantha, Prithviraj, Prashanth, Lorigan, Paul, Larkin, James, McArthur, Grant, Atkinson, Victoria, Millward, Michael, Khou, Muoi, Diem, Stefan, Ramanujam, Sangeetha, Kong, Ben, Liniker, Elizabeth, Guminski, Alexander, Parente, Phillip, Andrews, Miles C, Parakh, Sagun, Cebon, Jonathan, Long, Georgina V, Carlino, Matteo S, Klein, Oliver
Publicado 2017

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases

por Parakh, Sagun, Park, John J, Mendis, Shehara, Rai, Rajat, Xu, Wen, Lo, Serigne, Drummond, Martin, Rowe, Catherine, Wong, Annie, McArthur, Grant, Haydon, Andrew, Andrews, Miles C, Cebon, Jonathan, Guminski, Alex, Kefford, Richard F, Long, Georgina V, Menzies, Alexander M, Klein, Oliver, Carlino, Matteo S
Publicado 2017

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

por Galvani, Elena, Mundra, Piyushkumar A., Valpione, Sara, Garcia-Martinez, Pablo, Smith, Matthew, Greenall, Jonathan, Thakur, Rohit, Helmink, Beth, Andrews, Miles C., Boon, Louis, Chester, Christopher, Gremel, Gabriela, Hogan, Kate, Mandal, Amit, Zeng, Kang, Banyard, Antonia, Ashton, Garry, Cook, Martin, Lorigan, Paul, Wargo, Jennifer A., Dhomen, Nathalie, Marais, Richard
Publicado 2020

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

por Smith, Michael P, Rowling, Emily J, Miskolczi, Zsofia, Ferguson, Jennifer, Spoerri, Loredana, Haass, Nikolas K, Sloss, Olivia, McEntegart, Sophie, Arozarena, Imanol, von Kriegsheim, Alex, Rodriguez, Javier, Brunton, Holly, Kmarashev, Jivko, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Andrews, Miles C, Cooper, Zachary A, Flaherty, Keith T, Wargo, Jennifer A, Wellbrock, Claudia
Publicado 2017